Eikon reports 63.1% ORR in Phase 2 NSCLC trial of EIK1001; PARP1 inhibitor EIK1003 shows 24.5% ORR with paclitaxel

Eikon Therapeutics, Inc.

TeLuRide-005 Phase 2: ORR 63.1%, DCR 90.8% in 1L stage 4 NSCLC (n=65 evaluable).
Non-squamous cohort: ORR 55.6%, DCR 83.3%, median DOR >11 months at 13.6 months follow-up.
Squamous cohort: ORR 72.4%, DCR 100% with median follow-up 8.8 months (data maturing).
EIK1003 monotherapy (Cohort 1A): ORR 14.3% overall (26.7% PARP-naïve), median DOR 7.8 months in responders.
EIK1003 + paclitaxel (Cohort 1C): ORR 24.5% (29.6% in platinum-resistant ovarian, 19.2% in breast).

item 7.01 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-249725
form_type: 8-K
ticker: EIKN
cik: 0001861123
company_name: Eikon Therapeutics, Inc.
filed_at: 2026-06-01T11:30:25+00:00
discovered_at: 2026-06-01T11:35:00.280250+00:00
generated_at: 2026-06-01T11:35:37.963946+00:00
sec_items: ["7.01", "8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-249725
json_url: https://secwatch.observer/filing/0001193125-26-249725.json
markdown_url: https://secwatch.observer/filing/0001193125-26-249725.md
text_url: https://secwatch.observer/filing/0001193125-26-249725.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1861123/000119312526249725/0001193125-26-249725-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1861123/000119312526249725/eikn-20260530.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

DBX

Dropbox secures $400M revolving credit facility, authorizes $900M share repurchase program

DROPBOX, INC. June 1, 2026, 9:06 AM ET other_material Items 1.01, 2.03, 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

OPTU

Optimum raises $500M via preferred units, starts $300M tender at $2.50 to shield assets from CSC debt

Optimum Communications, Inc. June 1, 2026, 8:16 AM ET other_material Items 1.01, 3.02, 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

NXTC

NextCure Phase 1 SIM0505 data: 55% ORR in gynecologic cancers; cash into Q1 2027

NextCure, Inc. June 1, 2026, 8:10 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

JBIO

Jade Biosciences reports Phase 1 interim data: JADE101 shows ~70% IgA reduction, favorable safety, differentiated PK

Jade Biosciences, Inc. June 1, 2026, 7:55 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

GPRO

GoPro refiles financials with going-concern warning; potential defaults on debt

GoPro, Inc. June 1, 2026, 9:12 AM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

LIXT

Lixte Biotechnology pivots to AI energy infrastructure; appoints Denham Capital founder to board

LIXTE BIOTECHNOLOGY HOLDINGS, INC. June 1, 2026, 8:55 AM ET other_material Items 5.02, 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

BMNR

Bitmine holds 5.42M ETH (4.49% of supply); total crypto + cash = $11.6B

BITMINE IMMERSION TECHNOLOGIES, INC. June 1, 2026, 8:45 AM ET other_material Items 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

TTRX

Turn Therapeutics GX-03 Phase 2 interim: 92.6% EASI-50 at 4 weeks; no SAEs

Turn Therapeutics Inc. June 1, 2026, 8:45 AM ET other_material Items 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001193125-26-249725

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.